anticoagulants Flashcards

1
Q

unfractionated heparin MOA

A

binds to antithrombin III

inhibition of factor II and X

small platelet inhibition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

unfractionated heparin/LMWH antidote

A

protamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

heparin monitoring and normal ranges

A

PTT - 50-80 sec (1.5-3x baseline is therapeutic)

anti Xa - 0.3-0.7 U/mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

adverse effects of heparin

A

bleeding

skin necrosis, HIT, altered bone metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HIT diagnosis

A

antibody tests

4 T’s score

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HIT treatment

A

argatroban

also fondaparinux and bivalrudin but not FDA approved

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

LMWH MOA

A

binds w antithrombin to inhibit factor X

mild inhibition of factor II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

UFH vs LMWH

A

LMWH has more predictable response, less bleeding, no routine lab monitoring, able to be given as outpatient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

dosing adjustment for LMWH

A

renal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

bivalrudin MOA

A

direct thrombin inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

dosing adjustment for bivalrudin

A

renal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

bivalrudin dosing

A

0.1 mg/kg bolus, then 0.25 mg/kg/h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

argatroban MOA

A

direct thrombin inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

bivalrudin/argatroban monitoring

A

PTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

argatroban dosing

A

1.7-2.0 mcg/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

good anticoagulant & DOAC for renal impairment

A

argatroban

apixaban

17
Q

argatroban dosing adjustment

A

liver dysfunction

18
Q

fondaparinux MOA

A

long acting factor X inhibitor

19
Q

fondaparinux contraindication

A

CrCl<30

20
Q

warfarin MOA

A

inhibits production of vitamin K dependent clotting factors II, VII, IX and X

converts inactive vitamin K to active vitamin K

inhibits protein C and S

21
Q

warfarin half life

A

60 hours

max impact is 5-7 days

may need to bridge w lovenox

22
Q

warfarin dosing

A

5-7.5 mg daily, then titrate to INR (2-3) q 5-7 days

23
Q

warfarin AEs

A

bleeding (higher w fluconazole, amio, bactrim, metronizadole)
skin necrosis, purple toe syndrome, vasculitis

24
Q

warfarin & factor x inhibitors antidote

A

vitamin K, kcentra

25
Q

DOACs vs warfarin

A

DOACs more predictable, more rapid onset/offset, no routine monitoring, less risk of ICH and fatal hemorrhage

DOAC more expensive

warfarin indicated for mechanical valves

26
Q

dabigatran MOA

A

direct thrombin inhibitor

27
Q

rivaroxaban, apixaban, edoxaban MOA

A

factor Xa inhibitor

28
Q

periop considerations for dabigatran

A

may need to hold dose for up to 5 days before surgery depending on CrCl

29
Q

how long to hold factor X inhibitors before surgery

A

low risk procedures -24 h

high risk procedures - 48 h

30
Q

dabigatran antidote

A

idarucizumab

31
Q

anti xa inhibitors antidote

A

andexxa